SolasCure

Executive Summary

SolasCure is a UK-based biotechnology company founded in 2017 and headquartered in Oxford, dedicated to transforming chronic wound care. The company is developing Aurase Wound Gel, a novel biologic therapy that combines enzymatic debridement with activation of endogenous repair pathways. Unlike current standards of care that focus on maintenance and infection control, SolasCure aims to shift the treatment paradigm toward active tissue repair, addressing a significant unmet need in the growing chronic wound market. The company's platform leverages proprietary insights into wound healing biology to create a differentiated therapeutic approach. As a private, early-stage company, SolasCure has not yet disclosed specific funding rounds or clinical milestones, but the potential of its pipeline has attracted interest from wound care specialists. The company's strategy involves progressing Aurase Wound Gel through clinical development and establishing partnerships for manufacturing and commercialization. With the prevalence of chronic wounds rising due to aging populations and diabetes, SolasCure's innovative biologic approach could capture substantial market share if clinical efficacy is demonstrated. The company's focus on both debridement and repair positions it uniquely among competitors, offering a potential first-in-class therapy for complex wounds.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2a Clinical Trial Results for Aurase Wound Gel60% success
• Q3 2026Series A Financing Round70% success
• Q4 2026Strategic Partnership with a Major Wound Care Company50% success